MorphoSys AG (LTS:0NDV)

€ 66.8 0 (0%) Market Cap: 2.53 Bil Enterprise Value: 2.49 Bil PE Ratio: 0 PB Ratio: 51.57 GF Score: 45/100

Full Year 2023 MorphoSys AG Earnings Call Transcript
Mar 14, 2024

€66.11 (-0.44%)

Earnings
MorphoSys AG to be Acquired by Novartis AG Call Transcript
Feb 06, 2024
MorphoSys AG at JPMorgan Healthcare Conference Transcript
Jan 10, 2024
MorphoSys AG at ASH Meeting and Exposition Transcript
Dec 11, 2023
MorphoSys AG to Discuss MANIFEST-2 Results Transcript
Nov 21, 2023
Q3 2023 MorphoSys AG Earnings Call Transcript
Nov 16, 2023

€23.41 (-11.13%)

Earnings
MorphoSys AG at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2023
Half Year 2023 MorphoSys AG Earnings Call Transcript
Aug 10, 2023

€28.32 (+2.80%)

Earnings
MorphoSys AG Investor Call Focused on Pelabresib Transcript
Jun 21, 2023
MorphoSys AG at Goldman Sachs Healthcare Conference Transcript
Jun 13, 2023
Q1 2023 MorphoSys AG Earnings Call Transcript
May 04, 2023

€20.08 (+8.95%)

Earnings
Full Year 2022 MorphoSys AG Earnings Call Transcript
Mar 16, 2023

€14.65 (+4.85%)

Earnings
MorphoSys AG at JPMorgan Healthcare Conference Transcript
Jan 12, 2023
Q3 2022 MorphoSys AG Earnings Call Transcript
Nov 17, 2022

€14.75 (+2.75%)

Earnings
MorphoSys AG at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2022
Q2 2022 MorphoSys AG Earnings Call Transcript
Aug 04, 2022

€22.21 (-1.99%)

Earnings
MorphoSys AG at JMP Securities Life Sciences Conference Transcript
Jun 16, 2022
Q1 2022 MorphoSys AG Earnings Call Transcript
May 05, 2022

€19.16 (-1.87%)

Earnings
Full Year 2021 MorphoSys AG Earnings Call Transcript
Mar 17, 2022

€24.21 (+1.83%)

Earnings
MorphoSys AG at JPMorgan Healthcare Conference Transcript
Jan 12, 2022
Q3 2021 MorphoSys AG Earnings Call Transcript
Nov 11, 2021

€37.41 (-1.85%)

Earnings
MorphoSys AG at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 13, 2021
MorphoSys AG at Citi BioPharma Conference (Virtual) Transcript
Sep 09, 2021
Half Year 2021 MorphoSys AG Earnings Call Transcript
Jul 29, 2021

€47.39 (+3.39%)

Earnings
MorphoSys AG To Acquire Constellation Pharmaceuticals M&A Call Transcript
Jun 02, 2021
MorphoSys AG at UBS Global Healthcare Virtual Conference Transcript
May 25, 2021
Q1 2021 MorphoSys AG Earnings Call Transcript
May 06, 2021

€72.47 (+2.82%)

Earnings
Full Year 2020 MorphoSys AG Earnings Call Transcript
Mar 16, 2021

€75.63 (-10.18%)

Earnings
MorphoSys AG at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 13, 2021
Q3 2020 MorphoSys AG Earnings Call Transcript
Nov 12, 2020

€88.51 (-1.86%)

Earnings
MorphoSys AG and Incyte Corp to Discuss the Unmet Need and Global Opportunities for Tafasitamab in Non-Hodgkin Lymphomas Investor Call Transcript
Sep 29, 2020
Half Year 2020 MorphoSys AG Earnings Call Transcript
Aug 06, 2020

€110.3 (-4.95%)

Earnings
MorphoSys AG at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 10, 2020
Q1 2020 MorphoSys AG Earnings Call Transcript
May 07, 2020

€113.03 (+9.65%)

Earnings
Full Year 2019 MorphoSys AG Earnings Call Transcript
Mar 19, 2020

€71.68 (+1.24%)

Earnings
MorphoSys AG at JPMorgan Healthcare Conference Transcript
Jan 15, 2020
MorphoSys AG and Incyte Sign Global Collaboration and License Agreement for Tafasitamab Conference Call Transcript
Jan 13, 2020
Q3 2019 Morphosys AG Earnings Call Transcript
Oct 30, 2019

€98.75 (+4.00%)

Earnings
Half Year 2019 Morphosys AG Earnings Call Transcript
Aug 07, 2019

€108.9 (+3.22%)

Earnings
Morphosys AG To Discuss Results From The Primary Analysis Of The Ongoing Single-Arm Phase 2 Clinical Trial L-MIND Conference Call Transcript
May 20, 2019
Q1 2019 Morphosys AG Earnings Call Transcript
May 08, 2019

€94.4 (+3.96%)

Earnings
Full Year 2018 Morphosys AG Earnings Call Transcript
Mar 14, 2019

€86.75 (+0.81%)

Earnings

Q1 2023 MorphoSys AG Earnings Call Transcript

May 04, 2023 / 12:00PM GMT

Release Date Price: €20.08 (+8.95%)

Transcript

Operator

Ladies and gentlemen, thank you for standing by. Welcome, and thank you for joining the First Quarter Interim Statement 2023 of MorphoSys. (Operator Instructions) I would now like to turn the conference over to Julia Neugebauer. Please go ahead.

Julia Neugebauer

MorphoSys AG - Head of Investor Relations

Ladies and gentlemen, good afternoon or good morning. My name is Julia Neugebauer, Head of Investor Relations at MorphoSys, and it is my pleasure to welcome you to our first quarter 2023 financial results conference call.

Joining me on the call today are Jean-Paul Kress, Chief Executive Officer; Tim Demuth, Chief Research and Development Officer; and Joe Horvat, U.S. General Manager, who will join for the Q&A.

Before we begin, I'd like to remind you on Slide 2 that some of the statements made during the call today are forward-looking statements, including statements regarding our expectations for the commercialization of our products and our development plans, and expectations for the compounds in our pipeline as well as the development

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.